Treatment Sequencing and Unmet Needs in aRCC

2024 ASCO® Annual Meeting Insights Hub
M

ASCO® 2024 Insights: "Systemic Treatments in Favorable and Very Favorable Risk mRCC - Real-World Evidence From the IMDC"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Martin Zarba
By 2024 ASCO® Annual Meeting Insights Hub FEATURING Martin Zarba
235 views
June 7, 2024
0 Comments
Login to view comments. Click here to Login
09:54
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "1L Systemic Therapy Following Adjuvant IO…

Feat. T. El Zarif
23:31
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Harnessing the Immune System in RCC - Cur…

Feat. D. Braun
17:33
Benjamin Garmezy

1L Treatment Approaches in aRCC: Current Data, Treatment Selection, …

11:30
Northwestern Medicine Oncology and Hematology

HRQoL Data in aRCC: The Importance of Assessment and Impact on Clini…

Feat. D. Cella
04:50
Insights from 2024 ASCO® GU Annual Meeting

ASCO® GU 2024 Insights: "Nivo + Cabozantinib vs. Sunitinib for …

Feat. M. Bourlon
08:22
Pablo Maroto

Role of C-met, AXL, and VEGFR3 in Clear Cell Renal Cancer

22:03
Dana-Farber Cancer Institute

RCC Highlights From ASCO® GU 2024

Feat. W. Xu, T. Choueiri